The following is a summary of “Hematologic Cancers Among Patients With Type 2 Diabetes Prescribed GLP-1 Receptor Agonists,” ...

Despite a crowded GLP-1 drug development field, Structure's oral small molecule approach and strong financial position offer ...

NotCo announced Thursday the launch of its GLP Booster, a product that can be mixed into any food to naturally help you feel ...

Glucagon-like peptide 1 receptor agonists appear to reduce the risk of age-related macular degeneration and primary open-angle glaucoma.

There is initial evidence that low-dose semaglutide may reduce craving and drinking outcomes in individuals with alcohol-use disorder.

Investigating GLP-1 RAs reveals their impact on women's health, addressing metabolic disorders, reproductive health, and ...

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Researchers found that GLP-1 receptor agonists (GLP-1RAs) significantly reduce the risk of several blood cancers in type 2 ...

GLP-1 receptor agonists (GLP-1RAs) were initially approved for diabetes treatment (e.g., Ozempic®) but have revolutionized weight management ...

If you’ve been paying attention to the weight loss world, you’ve probably heard about GLP-1 receptor agonists like Ozempic, ...

For kidney transplant recipients with type 2 diabetes, use of glucagon-like peptide-1 receptor agonists was associated with ...

are taking GLP-1 — glucagon-like peptide-1 — receptor agonists, medications that were initially developed and FDA-approved to treat Type 2 diabetes are also being used off-label for weight ...